BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)

Bridge­Bio eyes US fil­ing for AT­TR-CM drug af­ter new PhI­II da­ta show ‘fastest’ clin­i­cal ben­e­fit to date

Bridge­Bio is prepar­ing to sub­mit an FDA fil­ing for its transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) drug can­di­date, dubbed aco­ramidis, be­fore the end of the year af­ter up­dat­ed reg­is­tra­tional da­ta in­di­cat­ed the treat­ment re­duced time to clin­i­cal ben­e­fit three­fold.

The Phase III AT­TRibute-CM tri­al stud­ied aco­ramidis ver­sus place­bo in 632 peo­ple with symp­to­matic AT­TR-CM. Topline da­ta pub­lished in Ju­ly showed the drug, at 30 months, met the tri­al’s com­pos­ite pri­ma­ry end­point, which mea­sured all-cause mor­tal­i­ty and car­dio­vas­cu­lar-re­lat­ed hos­pi­tal­iza­tion rates as well as changes from base­line in NT-proB­NP lev­els and the six-minute walk test (p<0.0001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.